Stories

The $250 billion market hiding in plain sight

11.03.25

The $250 billion market hiding in plain sight

It’s a common (and costly) misperception that investing in pandemic antiviral drug R&D is not profitable. A rigorous financial modeling tool developed by READDI and RTI Health Solutions quantifies the potentially astronomical ROI from a strategic portfolio of broad-spectrum antivirals.

READDI Forethought team advances drug discovery campaigns

08.28.25

READDI Forethought team advances drug discovery campaigns

READDI offers a global solution to a global challenge

05.23.25

READDI offers a global solution to a global challenge

Dengue therapeutics? Dr. Sophie Yacoub is cautiously optimistic

03.24.25

Dengue therapeutics? Dr. Sophie Yacoub is cautiously optimistic

READDI to partner with South Korea’s National Institute of Infectious Diseases, NIH, KDCA

03.17.25

READDI to partner with South Korea’s National Institute of Infectious Diseases, NIH, KDCA

‘Reinvigorate the therapeutics pipeline’ urges 100 Days Mission report

02.03.25

‘Reinvigorate the therapeutics pipeline’ urges 100 Days Mission report

Therapeutics Development Coalition offers hope

11.12.24

Therapeutics Development Coalition offers hope

Public health experts put out call for collaboration in antiviral therapeutics development coalition

08.30.24

Public health experts put out call for collaboration in antiviral therapeutics development coalition

UNC-Chapel Hill joins Japan-U.S. Research Collaboration symposium

08.28.24

UNC-Chapel Hill joins Japan-U.S. Research Collaboration symposium

READDI CEO joins global leaders in Brazil to push for pandemic readiness

08.08.24

READDI CEO joins global leaders in Brazil to push for pandemic readiness

READDI helps build a Therapeutics Coalition

07.10.24

READDI helps build a Therapeutics Coalition

How scary is H5N1 to a virologist raised on a Minnesota dairy farm?

07.01.24

How scary is H5N1 to a virologist raised on a Minnesota dairy farm?

Dengue is surging in the Americas

06.17.24

Dengue is surging in the Americas

The READDI Forethought team aims to treat current and future coronaviruses

05.20.24

The READDI Forethought team aims to treat current and future coronaviruses

READDI expertise guides 100 Days Mission Therapeutics Roadmap

02.15.24

READDI expertise guides 100 Days Mission Therapeutics Roadmap

READDI and SAS get ahead of the next pandemic with AI and machine-learning fueled drug discovery

02.08.24

READDI and SAS get ahead of the next pandemic with AI and machine-learning fueled drug discovery

Global coalition warns of bare R&D pipeline for pathogens with pandemic potential

01.24.24

Global coalition warns of bare R&D pipeline for pathogens with pandemic potential

READDI is filling the R&D pipeline for pandemic pathogens

01.22.24

READDI is filling the R&D pipeline for pandemic pathogens

Comprehensive antiviral landscape assessment guides R&D

11.13.23

Comprehensive antiviral landscape assessment guides R&D

Viral threats surge in a warming world

11.08.23

Viral threats surge in a warming world

Why READDI Inc.?

10.16.23

Why READDI Inc.?

Symposium underscores READDI’s role in ‘marathon of preparedness’

09.27.23

Symposium underscores READDI’s role in ‘marathon of preparedness’

Expert group makes strong case for medical-countermeasures network

09.18.23

Expert group makes strong case for medical-countermeasures network

A bipartisan opportunity to strengthen America’s pandemic security

08.28.23

A bipartisan opportunity to strengthen America’s pandemic security

How READDI develops drugs for viruses that don’t yet exist

08.21.23

How READDI develops drugs for viruses that don’t yet exist

READDI contributes to alliance in accelerating antiviral drug development

07.20.23

READDI contributes to alliance in accelerating antiviral drug development

READDI receives $65M grant from NIH to establish Antiviral Drug Discovery (AViDD) Center

05.20.22

READDI receives $65M grant from NIH to establish Antiviral Drug Discovery (AViDD) Center

READDI receives $18M from the N.C. General Assembly

02.11.22

READDI receives $18M from the N.C. General Assembly

READDI awarded $5M by RTI’s Forethought Research Collaboration Challenge

11.08.21

READDI awarded $5M by RTI’s Forethought Research Collaboration Challenge

SAS and UNC-Chapel Hill partner to accelerate antiviral drug development

09.14.21

SAS and UNC-Chapel Hill partner to accelerate antiviral drug development

The best time to fight a global pandemic is now.

And always.